Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases
Background Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extr...
Uloženo v:
| Vydáno v: | Annals of surgical oncology Ročník 30; číslo 7; s. 4444 - 4454 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Cham
Springer International Publishing
01.07.2023
Springer Nature B.V |
| Témata: | |
| ISSN: | 1068-9265, 1534-4681, 1534-4681 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extraperitoneal metastatic sites (EPMS) in this setting remains unclear.
Patients and Methods
Patients with CRPM undergoing complete cytoreduction in 2005–2018 were grouped in: peritoneal disease only (PDO), one EPMS (1 + EPMS), two or more EPMS (2 + EPMS). A retrospective analysis compared overall survival (OS) and postoperative outcomes.
Results
Of 433 patients, 109 had 1 + EPMS and 31 had 2 + EPMS. Overall, 101 patients had liver metastasis, 19 lung metastasis, and 30 retroperitoneal lymph node (RLN) invasion. The median OS was 56.9 months. There was no significant OS difference between PDO and 1 + EPMS groups (64.6 and 57.9 months, respectively), whereas OS was lower in the 2 + EPMS group (29.4 months,
p
= 0.005). In multivariate analysis, 2 + EPMS [hazard ratio (HR) 2.86, 95% confidence interval (CI) 1.33–6.12,
p
= 0.007], Sugarbaker’s Peritoneal Carcinomatosis Index (PCI) > 15 (HR 3.86, 95% CI 2.04–7.32,
p
< 0.001), poorly differentiated tumors (HR 2.62, 95% CI 1.21–5.66,
p
= 0.015), and
BRAF
mutation (HR 2.10, 95% CI 1.11–3.99,
p
= 0.024) were independent poor prognostic factors, while adjuvant chemotherapy was beneficial (HR 0.33, 95% CI 0.20–0.56,
p
< 0.001). Patients with liver resection did not show higher severe complication rates.
Conclusion
In patients with CRPM selected for a radical surgical approach, limited extraperitoneal disease involving one site, notably the liver, does not seem to significantly impair postoperative results. RLN invasion appeared as a poor prognostic factor in this population. |
|---|---|
| AbstractList | Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extraperitoneal metastatic sites (EPMS) in this setting remains unclear.
Patients with CRPM undergoing complete cytoreduction in 2005-2018 were grouped in: peritoneal disease only (PDO), one EPMS (1 + EPMS), two or more EPMS (2 + EPMS). A retrospective analysis compared overall survival (OS) and postoperative outcomes.
Of 433 patients, 109 had 1 + EPMS and 31 had 2 + EPMS. Overall, 101 patients had liver metastasis, 19 lung metastasis, and 30 retroperitoneal lymph node (RLN) invasion. The median OS was 56.9 months. There was no significant OS difference between PDO and 1 + EPMS groups (64.6 and 57.9 months, respectively), whereas OS was lower in the 2 + EPMS group (29.4 months, p = 0.005). In multivariate analysis, 2 + EPMS [hazard ratio (HR) 2.86, 95% confidence interval (CI) 1.33-6.12, p = 0.007], Sugarbaker's Peritoneal Carcinomatosis Index (PCI) > 15 (HR 3.86, 95% CI 2.04-7.32, p < 0.001), poorly differentiated tumors (HR 2.62, 95% CI 1.21-5.66, p = 0.015), and BRAF mutation (HR 2.10, 95% CI 1.11-3.99, p = 0.024) were independent poor prognostic factors, while adjuvant chemotherapy was beneficial (HR 0.33, 95% CI 0.20-0.56, p < 0.001). Patients with liver resection did not show higher severe complication rates.
In patients with CRPM selected for a radical surgical approach, limited extraperitoneal disease involving one site, notably the liver, does not seem to significantly impair postoperative results. RLN invasion appeared as a poor prognostic factor in this population. Background Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extraperitoneal metastatic sites (EPMS) in this setting remains unclear. Patients and Methods Patients with CRPM undergoing complete cytoreduction in 2005–2018 were grouped in: peritoneal disease only (PDO), one EPMS (1 + EPMS), two or more EPMS (2 + EPMS). A retrospective analysis compared overall survival (OS) and postoperative outcomes. Results Of 433 patients, 109 had 1 + EPMS and 31 had 2 + EPMS. Overall, 101 patients had liver metastasis, 19 lung metastasis, and 30 retroperitoneal lymph node (RLN) invasion. The median OS was 56.9 months. There was no significant OS difference between PDO and 1 + EPMS groups (64.6 and 57.9 months, respectively), whereas OS was lower in the 2 + EPMS group (29.4 months, p = 0.005). In multivariate analysis, 2 + EPMS [hazard ratio (HR) 2.86, 95% confidence interval (CI) 1.33–6.12, p = 0.007], Sugarbaker’s Peritoneal Carcinomatosis Index (PCI) > 15 (HR 3.86, 95% CI 2.04–7.32, p < 0.001), poorly differentiated tumors (HR 2.62, 95% CI 1.21–5.66, p = 0.015), and BRAF mutation (HR 2.10, 95% CI 1.11–3.99, p = 0.024) were independent poor prognostic factors, while adjuvant chemotherapy was beneficial (HR 0.33, 95% CI 0.20–0.56, p < 0.001). Patients with liver resection did not show higher severe complication rates. Conclusion In patients with CRPM selected for a radical surgical approach, limited extraperitoneal disease involving one site, notably the liver, does not seem to significantly impair postoperative results. RLN invasion appeared as a poor prognostic factor in this population. Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extraperitoneal metastatic sites (EPMS) in this setting remains unclear.BACKGROUNDSelected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extraperitoneal metastatic sites (EPMS) in this setting remains unclear.Patients with CRPM undergoing complete cytoreduction in 2005-2018 were grouped in: peritoneal disease only (PDO), one EPMS (1 + EPMS), two or more EPMS (2 + EPMS). A retrospective analysis compared overall survival (OS) and postoperative outcomes.PATIENTS AND METHODSPatients with CRPM undergoing complete cytoreduction in 2005-2018 were grouped in: peritoneal disease only (PDO), one EPMS (1 + EPMS), two or more EPMS (2 + EPMS). A retrospective analysis compared overall survival (OS) and postoperative outcomes.Of 433 patients, 109 had 1 + EPMS and 31 had 2 + EPMS. Overall, 101 patients had liver metastasis, 19 lung metastasis, and 30 retroperitoneal lymph node (RLN) invasion. The median OS was 56.9 months. There was no significant OS difference between PDO and 1 + EPMS groups (64.6 and 57.9 months, respectively), whereas OS was lower in the 2 + EPMS group (29.4 months, p = 0.005). In multivariate analysis, 2 + EPMS [hazard ratio (HR) 2.86, 95% confidence interval (CI) 1.33-6.12, p = 0.007], Sugarbaker's Peritoneal Carcinomatosis Index (PCI) > 15 (HR 3.86, 95% CI 2.04-7.32, p < 0.001), poorly differentiated tumors (HR 2.62, 95% CI 1.21-5.66, p = 0.015), and BRAF mutation (HR 2.10, 95% CI 1.11-3.99, p = 0.024) were independent poor prognostic factors, while adjuvant chemotherapy was beneficial (HR 0.33, 95% CI 0.20-0.56, p < 0.001). Patients with liver resection did not show higher severe complication rates.RESULTSOf 433 patients, 109 had 1 + EPMS and 31 had 2 + EPMS. Overall, 101 patients had liver metastasis, 19 lung metastasis, and 30 retroperitoneal lymph node (RLN) invasion. The median OS was 56.9 months. There was no significant OS difference between PDO and 1 + EPMS groups (64.6 and 57.9 months, respectively), whereas OS was lower in the 2 + EPMS group (29.4 months, p = 0.005). In multivariate analysis, 2 + EPMS [hazard ratio (HR) 2.86, 95% confidence interval (CI) 1.33-6.12, p = 0.007], Sugarbaker's Peritoneal Carcinomatosis Index (PCI) > 15 (HR 3.86, 95% CI 2.04-7.32, p < 0.001), poorly differentiated tumors (HR 2.62, 95% CI 1.21-5.66, p = 0.015), and BRAF mutation (HR 2.10, 95% CI 1.11-3.99, p = 0.024) were independent poor prognostic factors, while adjuvant chemotherapy was beneficial (HR 0.33, 95% CI 0.20-0.56, p < 0.001). Patients with liver resection did not show higher severe complication rates.In patients with CRPM selected for a radical surgical approach, limited extraperitoneal disease involving one site, notably the liver, does not seem to significantly impair postoperative results. RLN invasion appeared as a poor prognostic factor in this population.CONCLUSIONIn patients with CRPM selected for a radical surgical approach, limited extraperitoneal disease involving one site, notably the liver, does not seem to significantly impair postoperative results. RLN invasion appeared as a poor prognostic factor in this population. BackgroundSelected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extraperitoneal metastatic sites (EPMS) in this setting remains unclear.Patients and MethodsPatients with CRPM undergoing complete cytoreduction in 2005–2018 were grouped in: peritoneal disease only (PDO), one EPMS (1 + EPMS), two or more EPMS (2 + EPMS). A retrospective analysis compared overall survival (OS) and postoperative outcomes.ResultsOf 433 patients, 109 had 1 + EPMS and 31 had 2 + EPMS. Overall, 101 patients had liver metastasis, 19 lung metastasis, and 30 retroperitoneal lymph node (RLN) invasion. The median OS was 56.9 months. There was no significant OS difference between PDO and 1 + EPMS groups (64.6 and 57.9 months, respectively), whereas OS was lower in the 2 + EPMS group (29.4 months, p = 0.005). In multivariate analysis, 2 + EPMS [hazard ratio (HR) 2.86, 95% confidence interval (CI) 1.33–6.12, p = 0.007], Sugarbaker’s Peritoneal Carcinomatosis Index (PCI) > 15 (HR 3.86, 95% CI 2.04–7.32, p < 0.001), poorly differentiated tumors (HR 2.62, 95% CI 1.21–5.66, p = 0.015), and BRAF mutation (HR 2.10, 95% CI 1.11–3.99, p = 0.024) were independent poor prognostic factors, while adjuvant chemotherapy was beneficial (HR 0.33, 95% CI 0.20–0.56, p < 0.001). Patients with liver resection did not show higher severe complication rates.ConclusionIn patients with CRPM selected for a radical surgical approach, limited extraperitoneal disease involving one site, notably the liver, does not seem to significantly impair postoperative results. RLN invasion appeared as a poor prognostic factor in this population. |
| Author | Schell, Frédéric Rousset, Pascal Omar, Alhadeedi Villeneuve, Laurent Kefleyesus, Amaniel Péron, Julien Glehen, Olivier Passot, Guillaume Kepenekian, Vahan Benzerdjeb, Nazim |
| Author_xml | – sequence: 1 givenname: Frédéric surname: Schell fullname: Schell, Frédéric organization: Surgical Oncology Department, Hôpital Lyon Sud - Service de Chirurgie Digestive et Oncologique, Hospices Civils de Lyon, EA3738 CICLY, Université Claude Bernard Lyon 1 (UVBL1) – sequence: 2 givenname: Amaniel surname: Kefleyesus fullname: Kefleyesus, Amaniel organization: Surgical Oncology Department, Hôpital Lyon Sud - Service de Chirurgie Digestive et Oncologique, Hospices Civils de Lyon, Department of Visceral Surgery, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL) – sequence: 3 givenname: Nazim surname: Benzerdjeb fullname: Benzerdjeb, Nazim organization: EA3738 CICLY, Université Claude Bernard Lyon 1 (UVBL1), Department of Pathology, Hospices Civils de Lyon, Hôpital Lyon Sud – sequence: 4 givenname: Guillaume surname: Passot fullname: Passot, Guillaume organization: Surgical Oncology Department, Hôpital Lyon Sud - Service de Chirurgie Digestive et Oncologique, Hospices Civils de Lyon, EA3738 CICLY, Université Claude Bernard Lyon 1 (UVBL1) – sequence: 5 givenname: Pascal surname: Rousset fullname: Rousset, Pascal organization: EA3738 CICLY, Université Claude Bernard Lyon 1 (UVBL1), Department of Radiology, Hospices Civils de Lyon, Hôpital Lyon Sud – sequence: 6 givenname: Alhadeedi surname: Omar fullname: Omar, Alhadeedi organization: Surgical Oncology Department, Hôpital Lyon Sud - Service de Chirurgie Digestive et Oncologique, Hospices Civils de Lyon, EA3738 CICLY, Université Claude Bernard Lyon 1 (UVBL1) – sequence: 7 givenname: Laurent surname: Villeneuve fullname: Villeneuve, Laurent organization: EA3738 CICLY, Université Claude Bernard Lyon 1 (UVBL1) – sequence: 8 givenname: Julien surname: Péron fullname: Péron, Julien organization: Medical Oncology Department, Hôpital Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon I, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé – sequence: 9 givenname: Olivier surname: Glehen fullname: Glehen, Olivier organization: Surgical Oncology Department, Hôpital Lyon Sud - Service de Chirurgie Digestive et Oncologique, Hospices Civils de Lyon, EA3738 CICLY, Université Claude Bernard Lyon 1 (UVBL1) – sequence: 10 givenname: Vahan surname: Kepenekian fullname: Kepenekian, Vahan email: vahan.kepenekian@chu-lyon.fr organization: Surgical Oncology Department, Hôpital Lyon Sud - Service de Chirurgie Digestive et Oncologique, Hospices Civils de Lyon, EA3738 CICLY, Université Claude Bernard Lyon 1 (UVBL1) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36864324$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kV1rFTEQhoO02Pa0f8ALWfDGm23zuUku5VD1QIte2OuQk52tW3aTY5IV_fdOPbWFIoVAQniemWHeE3IQUwRC3jB6zrhUF4VRKWRLuWiZ4Nq29hU5Zgq_ZGfYAb5pZ1rLO3VETkq5o5RpQdVrciQ600nB5TGZN3GYFogBmjQ0l79q9jvIY8VOfmquofqCB0qTYlO_Q7Nesq_jT2g3sUKszbWP_hbm-yf66zSlDKGi-vV_VU7J4eCnAmcP94rcfLz8tv7cXn35tFl_uGqD0Kq2GmzPdG-sUDB4K0QAavpeWxFosKGjzOuhAyl9B2breyMNV7AdjBLWCj6IFXm_r7vL6ccCpbp5LAGmyUdIS3FcGyGtFlYh-u4ZepeWHHE6x7Gqwi0hvCJvH6hlO0Pvdnmcff7t_i0SAb4HQk6lZBgeEUbdfVpun5bDtNzftJxFyTyTwlhxvSliDOP0sir2asE-8Rby09gvWH8AbYeprw |
| CitedBy_id | crossref_primary_10_1002_jso_27944 crossref_primary_10_1245_s10434_023_13320_x crossref_primary_10_1245_s10434_023_14840_2 crossref_primary_10_1245_s10434_025_18022_0 crossref_primary_10_2147_OTT_S448024 crossref_primary_10_1245_s10434_024_15694_y crossref_primary_10_1016_j_ejso_2024_108788 crossref_primary_10_1245_s10434_024_15942_1 crossref_primary_10_1245_s10434_024_14929_2 |
| Cites_doi | 10.1200/JCO.1995.13.1.8 10.1016/S1470-2045(20)30599-4 10.1007/978-1-4613-1247-5_23 10.1080/02656736.2019.1635717 10.21037/apm-20-919 10.1245/s10434-015-5005-2 10.1016/j.ygyno.2018.06.022 10.1046/j.1365-2168.2002.02274.x 10.1093/annonc/mdw235 10.1016/j.ejso.2020.08.006 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O 10.1097/SLA.0b013e31827e9289 10.1016/j.ejso.2020.07.038 10.1245/ASO.2003.01.018 10.1016/j.ctrv.2012.11.003 10.1016/j.ejso.2015.03.229 10.1007/s00423-019-01787-w 10.1097/00000658-199501000-00004 10.1016/S0090-4295(02)02163-5 10.4143/crt.2017.100 10.1016/j.ejso.2018.10.540 10.1245/s10434-021-10190-z 10.1080/17474124.2020.1760839 10.1200/JCO.22.00839 10.1016/j.ejca.2020.08.009 10.3390/jcm10102131 10.1159/000454687 10.1245/s10434-014-4173-9 10.1016/j.ejso.2020.07.041 10.1177/14574969221083394 10.1097/SLA.0b013e318255486a 10.1016/j.ejca.2008.10.026 10.1016/j.ygyno.2009.12.010 10.1016/S1470-2045(16)30500-9 10.1200/JCO.20.01225 |
| ContentType | Journal Article |
| Copyright | Society of Surgical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2023. Society of Surgical Oncology. |
| Copyright_xml | – notice: Society of Surgical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2023. Society of Surgical Oncology. |
| DBID | AAYXX CITATION NPM 3V. 7TO 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1245/s10434-023-13279-9 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic Oncogenes and Growth Factors Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1534-4681 |
| EndPage | 4454 |
| ExternalDocumentID | 36864324 10_1245_s10434_023_13279_9 |
| Genre | Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 1SB 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2WC 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6J9 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BAWUL BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C1A CAG CCPQU COF CS3 CSCUP DDRTE DIK DL5 DNIVK DPUIP E3Z EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GX1 GXS H13 HEOXT HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IH2 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD OWW P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOQ YFH YLTOR Z45 Z7U Z7X Z82 Z83 Z87 Z8O Z8V Z91 ZMTXR ZOVNA AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c375t-7e9d17d8935efa933ce08dd793c0c9c601a7f6e44a6e8bad84825ebf8539932f3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 9 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000942970100006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1068-9265 1534-4681 |
| IngestDate | Fri Sep 05 08:08:33 EDT 2025 Wed Nov 05 14:44:13 EST 2025 Thu Apr 03 07:03:05 EDT 2025 Tue Nov 18 21:43:41 EST 2025 Sat Nov 29 01:47:52 EST 2025 Fri Feb 21 02:43:14 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | 2023. Society of Surgical Oncology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c375t-7e9d17d8935efa933ce08dd793c0c9c601a7f6e44a6e8bad84825ebf8539932f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 36864324 |
| PQID | 2825532478 |
| PQPubID | 32486 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2783497395 proquest_journals_2825532478 pubmed_primary_36864324 crossref_primary_10_1245_s10434_023_13279_9 crossref_citationtrail_10_1245_s10434_023_13279_9 springer_journals_10_1245_s10434_023_13279_9 |
| PublicationCentury | 2000 |
| PublicationDate | 20230700 |
| PublicationDateYYYYMMDD | 2023-07-01 |
| PublicationDate_xml | – month: 7 year: 2023 text: 20230700 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: United States – name: New York |
| PublicationTitle | Annals of surgical oncology |
| PublicationTitleAbbrev | Ann Surg Oncol |
| PublicationTitleAlternate | Ann Surg Oncol |
| PublicationYear | 2023 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | Holch, Demmer, Lamersdorf (CR4) 2017; 33 Chandy, Saxby, Pang, Sharma (CR28) 2021; 10 Hübner, Kusamura, Villeneuve (CR16) 2020; 46 Eisenhauer, Therasse, Bogaerts (CR20) 2009; 45 Goere, Malka, Tzanis (CR7) 2013; 257 Jayne, Fook, Loi (CR8) 2002; 89 de Cuba, Kwakman, Knol (CR11) 2013; 39 CR15 Franko, Shi, Meyers (CR5) 2016; 17 Pinto, Hobeika, Philis (CR10) 2019; 404 Passot, Vaudoyer, Cotte (CR37) 2012; 256 Rossini, Antoniotti, Lonardi (CR13) 2022; 40 Dico, Faron, Yonemura (CR9) 2021; 47 CR12 Han, Pantuck, Bui (CR30) 2003; 61 Jobsen, ten Cate, Lybeert (CR32) 2010; 117 Moretto, Rossini, Zucchelli (CR2) 2020; 139 Sadeghi, Arvieux, Glehen (CR27) 2000; 88 Mercier, Mohamed, Cazauran (CR23) 2019; 36 Alyami, Kim, Villeneuve (CR25) 2017; 34 Glehen, Osinsky, Cotte (CR24) 2003; 10 Deng, Yang, Tan (CR29) 2018; 150 Bae, Hur, Min (CR35) 2017; 50 Hübner, Kusamura, Villeneuve (CR17) 2020; 46 Jacquet, Sugarbaker (CR21) 1996; 82 Boukili, Flaris, Mercier (CR18) 2022; 111 Hellman, Weichselbaum (CR1) 1995; 13 Molla, Fernandez-Plana, Albiol (CR14) 2021; 10 Chen, Deng, Yang (CR31) 2020; 14 Cutsem, Cervantes, Adam (CR3) 2016; 27 Sugarbaker (CR22) 1995; 221 Gagnière, Dupré, Chabaud (CR34) 2015; 41 Mohkam, Passot, Cotte (CR19) 2016; 23 Quenet, Elias, Roca (CR6) 2021; 22 Bakkers, Lurvink, Rijken (CR26) 2021; 28 van der Werf, Wassenaar, de Niet (CR33) 2019; 45 Salah, Ardissone, Gonzalez (CR36) 2015; 22 13279_CR15 IE Boukili (13279_CR18) 2022; 111 M Hübner (13279_CR17) 2020; 46 EV Cutsem (13279_CR3) 2016; 27 JW Holch (13279_CR4) 2017; 33 G Passot (13279_CR37) 2012; 256 M Alyami (13279_CR25) 2017; 34 A Pinto (13279_CR10) 2019; 404 EMV de Cuba (13279_CR11) 2013; 39 R Moretto (13279_CR2) 2020; 139 J Franko (13279_CR5) 2016; 17 D Goere (13279_CR7) 2013; 257 K Chen (13279_CR31) 2020; 14 SU Bae (13279_CR35) 2017; 50 F Mercier (13279_CR23) 2019; 36 S Hellman (13279_CR1) 1995; 13 B Sadeghi (13279_CR27) 2000; 88 RL Dico (13279_CR9) 2021; 47 M Molla (13279_CR14) 2021; 10 D Rossini (13279_CR13) 2022; 40 K Deng (13279_CR29) 2018; 150 DG Jayne (13279_CR8) 2002; 89 M Hübner (13279_CR16) 2020; 46 LR van der Werf (13279_CR33) 2019; 45 PH Sugarbaker (13279_CR22) 1995; 221 F Quenet (13279_CR6) 2021; 22 P Jacquet (13279_CR21) 1996; 82 S Salah (13279_CR36) 2015; 22 JJ Jobsen (13279_CR32) 2010; 117 C Bakkers (13279_CR26) 2021; 28 O Glehen (13279_CR24) 2003; 10 ETJ Chandy (13279_CR28) 2021; 10 K-R Han (13279_CR30) 2003; 61 J Gagnière (13279_CR34) 2015; 41 EA Eisenhauer (13279_CR20) 2009; 45 13279_CR12 K Mohkam (13279_CR19) 2016; 23 |
| References_xml | – volume: 13 start-page: 8 year: 1995 end-page: 10 ident: CR1 article-title: Oligometastases publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.1.8 – volume: 22 start-page: 256 year: 2021 end-page: 266 ident: CR6 article-title: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30599-4 – volume: 82 start-page: 359 year: 1996 end-page: 374 ident: CR21 article-title: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis publication-title: Cancer Treat Res doi: 10.1007/978-1-4613-1247-5_23 – volume: 36 start-page: 744 year: 2019 end-page: 752 ident: CR23 article-title: An update of peritonectomy procedures used in cytoreductive surgery for peritoneal malignancy publication-title: Int J Hyperth doi: 10.1080/02656736.2019.1635717 – volume: 10 start-page: 5988 year: 2021 end-page: 6001 ident: CR28 article-title: The multidisciplinary management of oligometastases from colorectal cancer: a narrative review publication-title: Ann Palliat Med doi: 10.21037/apm-20-919 – volume: 23 start-page: 1261 year: 2016 end-page: 1270 ident: CR19 article-title: Resectability of peritoneal carcinomatosis: learnings from a prospective cohort of 533 consecutive patients selected for cytoreductive surgery publication-title: Ann Surg Oncol doi: 10.1245/s10434-015-5005-2 – volume: 150 start-page: 460 year: 2018 end-page: 465 ident: CR29 article-title: Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2018.06.022 – ident: CR12 – volume: 89 start-page: 1545 year: 2002 end-page: 1550 ident: CR8 article-title: Peritoneal carcinomatosis from colorectal cancer publication-title: Br J Surg doi: 10.1046/j.1365-2168.2002.02274.x – volume: 27 start-page: 1386 year: 2016 end-page: 1422 ident: CR3 article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer publication-title: Ann oncol doi: 10.1093/annonc/mdw235 – volume: 46 start-page: 2311 year: 2020 end-page: 2323 ident: CR17 article-title: Guidelines for perioperative care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) society recommendations—part II: postoperative management and special considerations publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.08.006 – volume: 88 start-page: 358 year: 2000 end-page: 363 ident: CR27 article-title: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study publication-title: Cancer doi: 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O – volume: 257 start-page: 1065 year: 2013 end-page: 1071 ident: CR7 article-title: Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? publication-title: Ann Surg doi: 10.1097/SLA.0b013e31827e9289 – volume: 47 start-page: 89 year: 2021 end-page: 100 ident: CR9 article-title: Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI) publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.07.038 – volume: 10 start-page: 863 year: 2003 end-page: 869 ident: CR24 article-title: Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures publication-title: Ann Surg Oncol doi: 10.1245/ASO.2003.01.018 – volume: 39 start-page: 321 year: 2013 end-page: 327 ident: CR11 article-title: Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2012.11.003 – volume: 41 start-page: 731 year: 2015 end-page: 737 ident: CR34 article-title: Retroperitoneal nodal metastases from colorectal cancer: Curable metastases with radical retroperitoneal lymphadenectomy in selected patients publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2015.03.229 – volume: 404 start-page: 477 year: 2019 end-page: 488 ident: CR10 article-title: Synchronous liver metastases and peritoneal carcinomatosis from colorectal cancer: different strategies for curative treatment? publication-title: Langenbecks Arch Surg doi: 10.1007/s00423-019-01787-w – volume: 221 start-page: 29 year: 1995 end-page: 42 ident: CR22 article-title: Peritonectomy procedures publication-title: Ann Surg doi: 10.1097/00000658-199501000-00004 – volume: 61 start-page: 314 year: 2003 end-page: 319 ident: CR30 article-title: Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma publication-title: Urology doi: 10.1016/S0090-4295(02)02163-5 – volume: 50 start-page: 712 year: 2017 end-page: 719 ident: CR35 article-title: Which patients with isolated para-aortic lymph node metastasis will truly benefit from extended lymph node dissection for colon cancer? publication-title: Cancer Res Treat doi: 10.4143/crt.2017.100 – volume: 45 start-page: 376 year: 2019 end-page: 382 ident: CR33 article-title: The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2018.10.540 – volume: 28 start-page: 9073 year: 2021 end-page: 9083 ident: CR26 article-title: Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study publication-title: Ann Surg Oncol doi: 10.1245/s10434-021-10190-z – volume: 14 start-page: 491 year: 2020 end-page: 497 ident: CR31 article-title: Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study publication-title: Expert Rev Gastroent doi: 10.1080/17474124.2020.1760839 – volume: 40 start-page: 2878 year: 2022 end-page: 2888 ident: CR13 article-title: Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer: the phase III TRIPLETE study by GONO publication-title: J Clin Oncol doi: 10.1200/JCO.22.00839 – ident: CR15 – volume: 139 start-page: 81 year: 2020 end-page: 89 ident: CR2 article-title: Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy–a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.08.009 – volume: 10 start-page: 2131 year: 2021 ident: CR14 article-title: Limited liver or lung colorectal cancer metastases. Systemic treatment, surgery, ablation or SBRT publication-title: J Clin Med doi: 10.3390/jcm10102131 – volume: 33 start-page: 70 year: 2017 end-page: 75 ident: CR4 article-title: Pattern and dynamics of distant metastases in metastatic colorectal cancer publication-title: Visc Med doi: 10.1159/000454687 – volume: 22 start-page: 1844 year: 2015 end-page: 1850 ident: CR36 article-title: Pulmonary metastasectomy in colorectal cancer patients with previously resected liver metastasis: pooled analysis publication-title: Ann Surg Oncol doi: 10.1245/s10434-014-4173-9 – volume: 46 start-page: 2292 year: 2020 end-page: 2310 ident: CR16 article-title: Guidelines for perioperative care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) society recommendations—part I: preoperative and intraoperative management publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.07.041 – volume: 111 start-page: 145749692210833 year: 2022 ident: CR18 article-title: Prehabilitation before major abdominal surgery: evaluation of the impact of a perioperative clinical pathway, a pilot study publication-title: Scand J Surg doi: 10.1177/14574969221083394 – volume: 34 start-page: 1 year: 2017 end-page: 6 ident: CR25 article-title: Ninety-day post-operative morbidity and mortality using the National Cancer Institute’s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy publication-title: Int J Hyperthermia – volume: 256 start-page: 125 year: 2012 end-page: 129 ident: CR37 article-title: Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis publication-title: Ann Surg doi: 10.1097/SLA.0b013e318255486a – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: CR20 article-title: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 117 start-page: 32 year: 2010 end-page: 36 ident: CR32 article-title: The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2009.12.010 – volume: 17 start-page: 1709 year: 2016 end-page: 1719 ident: CR5 article-title: Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30500-9 – volume: 22 start-page: 256 year: 2021 ident: 13279_CR6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30599-4 – volume: 45 start-page: 376 year: 2019 ident: 13279_CR33 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2018.10.540 – volume: 256 start-page: 125 year: 2012 ident: 13279_CR37 publication-title: Ann Surg doi: 10.1097/SLA.0b013e318255486a – volume: 17 start-page: 1709 year: 2016 ident: 13279_CR5 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30500-9 – volume: 10 start-page: 2131 year: 2021 ident: 13279_CR14 publication-title: J Clin Med doi: 10.3390/jcm10102131 – volume: 150 start-page: 460 year: 2018 ident: 13279_CR29 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2018.06.022 – volume: 22 start-page: 1844 year: 2015 ident: 13279_CR36 publication-title: Ann Surg Oncol doi: 10.1245/s10434-014-4173-9 – volume: 40 start-page: 2878 year: 2022 ident: 13279_CR13 publication-title: J Clin Oncol doi: 10.1200/JCO.22.00839 – volume: 36 start-page: 744 year: 2019 ident: 13279_CR23 publication-title: Int J Hyperth doi: 10.1080/02656736.2019.1635717 – volume: 13 start-page: 8 year: 1995 ident: 13279_CR1 publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.1.8 – volume: 34 start-page: 1 year: 2017 ident: 13279_CR25 publication-title: Int J Hyperthermia – volume: 61 start-page: 314 year: 2003 ident: 13279_CR30 publication-title: Urology doi: 10.1016/S0090-4295(02)02163-5 – volume: 14 start-page: 491 year: 2020 ident: 13279_CR31 publication-title: Expert Rev Gastroent doi: 10.1080/17474124.2020.1760839 – volume: 10 start-page: 5988 year: 2021 ident: 13279_CR28 publication-title: Ann Palliat Med doi: 10.21037/apm-20-919 – volume: 111 start-page: 145749692210833 year: 2022 ident: 13279_CR18 publication-title: Scand J Surg doi: 10.1177/14574969221083394 – volume: 82 start-page: 359 year: 1996 ident: 13279_CR21 publication-title: Cancer Treat Res doi: 10.1007/978-1-4613-1247-5_23 – volume: 88 start-page: 358 year: 2000 ident: 13279_CR27 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O – ident: 13279_CR12 doi: 10.1200/JCO.20.01225 – volume: 89 start-page: 1545 year: 2002 ident: 13279_CR8 publication-title: Br J Surg doi: 10.1046/j.1365-2168.2002.02274.x – volume: 46 start-page: 2292 year: 2020 ident: 13279_CR16 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.07.041 – ident: 13279_CR15 – volume: 257 start-page: 1065 year: 2013 ident: 13279_CR7 publication-title: Ann Surg doi: 10.1097/SLA.0b013e31827e9289 – volume: 33 start-page: 70 year: 2017 ident: 13279_CR4 publication-title: Visc Med doi: 10.1159/000454687 – volume: 221 start-page: 29 year: 1995 ident: 13279_CR22 publication-title: Ann Surg doi: 10.1097/00000658-199501000-00004 – volume: 39 start-page: 321 year: 2013 ident: 13279_CR11 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2012.11.003 – volume: 27 start-page: 1386 year: 2016 ident: 13279_CR3 publication-title: Ann oncol doi: 10.1093/annonc/mdw235 – volume: 47 start-page: 89 year: 2021 ident: 13279_CR9 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.07.038 – volume: 28 start-page: 9073 year: 2021 ident: 13279_CR26 publication-title: Ann Surg Oncol doi: 10.1245/s10434-021-10190-z – volume: 46 start-page: 2311 year: 2020 ident: 13279_CR17 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2020.08.006 – volume: 45 start-page: 228 year: 2009 ident: 13279_CR20 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 23 start-page: 1261 year: 2016 ident: 13279_CR19 publication-title: Ann Surg Oncol doi: 10.1245/s10434-015-5005-2 – volume: 139 start-page: 81 year: 2020 ident: 13279_CR2 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.08.009 – volume: 50 start-page: 712 year: 2017 ident: 13279_CR35 publication-title: Cancer Res Treat doi: 10.4143/crt.2017.100 – volume: 117 start-page: 32 year: 2010 ident: 13279_CR32 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2009.12.010 – volume: 10 start-page: 863 year: 2003 ident: 13279_CR24 publication-title: Ann Surg Oncol doi: 10.1245/ASO.2003.01.018 – volume: 404 start-page: 477 year: 2019 ident: 13279_CR10 publication-title: Langenbecks Arch Surg doi: 10.1007/s00423-019-01787-w – volume: 41 start-page: 731 year: 2015 ident: 13279_CR34 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2015.03.229 |
| SSID | ssj0017305 |
| Score | 2.459851 |
| Snippet | Background
Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal... Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach... BackgroundSelected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4444 |
| SubjectTerms | Chemotherapy Colorectal cancer Colorectal carcinoma Gastric cancer Liver Lung cancer Lymph nodes Medical prognosis Medicine Medicine & Public Health Metastases Metastasis Multivariate analysis Oncology Peritoneal diseases Peritoneal Surface Malignancy Peritoneum Radiation therapy Surgery Surgical Oncology |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxxBDA_WSumLba2226qs4Fs7cHfz_SjHSQueSP3At2V2PkDQO7ndK_3zm-zHSdEW7PNOMstMMklI8gvAoTLCubIcMgKvY0ImjzonS6Z40MMyphRig65_ok9PzfW1Peuawqq-2r1PSTYvdYOAICQ1uwkuGNoYhhGUtsy-gJdo7gyp44_zq1XuAGVWNjlOhao8UrJrlXmax5_m6JGP-Sg_2pid4zf_98NvYbNzM_OjVi7ewVqcbcGraZdIfw933_vhJPk85ZNfNTVhLW4ImRvJprF26DVWscrnsxxdxHy8bBHCWVPyXucPVTNEP8YXlF5OJD17iss2XB5PLsbfWDd5gXmuZc10tGGoA_oyMiZnOfdxYEJAXfYDbz0GcU4nFYVwKprSBSMw0IxlMoRzy0eJ78D6DPf6CHkZuBwMylFAjiKhZAjrCaDHpqCdMqMMhv0FFL6DJafpGLcFhSd4jkV7jgWeY9GcY2Ez-LKiuW9BOf65ere_16JT0Kqgll2JzqQ2GRysPqNqUb7EzeJ8iWtoCImlTGYGH1p5WG3HlVEEZpjB1_7yH5j__V8-PW_5Z3hN4-3b8uBdWK8Xy7gHG_5nfVMt9hux_w3Z-_uo priority: 102 providerName: Springer Nature |
| Title | Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases |
| URI | https://link.springer.com/article/10.1245/s10434-023-13279-9 https://www.ncbi.nlm.nih.gov/pubmed/36864324 https://www.proquest.com/docview/2825532478 https://www.proquest.com/docview/2783497395 |
| Volume | 30 |
| WOSCitedRecordID | wos000942970100006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1534-4681 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017305 issn: 1068-9265 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEB-8PRFf_P6onkcF3zS42yRN8iS67KHgLcv5wb6VNB9woLvntiv--c606S5yei--FEozScrMJJPMzG8AXpRaWFvXE0bgdUzI6FDnZM1K7tWkDjH60KHrf1TzuV4uzSJduDUprHJYE7uF2q8d3ZG_phxLibu_0m8ufjCqGkXe1VRC4wAOCalMjODw3Wy-ONv5EVB-ZefvLFGti1KmtJlCSEqeE1ww3LMYnsiUYebPremSvXnJV9ptQSe3_3fyd-BWMj7zt7203IVrYXUPbpwm9_p9-P5hKFmSr2M--9VSatbmnPC6kew0tBZtySY0-XqVo-GYT7c9bjjrAuHbfB9LQ_RTXFdpPUXSxd96eQBfTmafp-9ZqsfAHFeyZSoYP1EeLRwZojWcuzDW3qOGu7EzDo92VsUyCGHLoGvrtcDfDnXUhH7Li8gfwmiFYz2GvPZcjsd14bFHEVFehHEE22OiV7bURQaTgRWVS2DlVDPjW0WHFmRf1bOvQvZVHfsqk8HLHc1FD9VxZeujgVVVUtum2vMpg-e7z6hw5EWxq7DeYhsqTWLIv5nBo14ydsPxUpcEcZjBq0FU9p3_ey5Prp7LU7hJRe77IOEjGLWbbXgG193P9rzZHMOBWqruqY-T-OPb2aevvwE_wgnq |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgigX3gVDgUWCE6yI7V2v94AQCq0aNYl6KFJuZr0PqRIkJXZ4_Cl-IzN-JEKF3nrg7H348c3MjmfmG4AXWS6MKcuYE3kdFzJYlDlZ8ix1Ki59CM437PpjNZ3ms5k-3oJffS0MpVX2OrFR1G5h6R_5G6qxlGj9Vf7u7CunrlEUXe1baLSwOPI_v6PLVr0dfcDv-zJJDvZPhoe86yrAbapkzZXXLlYO7bT0waA_b_0gdw5xagdWW3RQjAqZF8JkPi-NywXu7MuQE4drmoQU170CV1GPK0ohU7O1gxejtMgmupqhEkky2RXpJEJSqZ5IBUcLydH_U5rrPw3hudPtuchsY_AObv1vr-o23OyO1ux9Kwt3YMvP78L1SZc8cA--jPqGLGwR2P6PmgrPlqfERo7TJr42eFKufMUWc4bHYjZctazovEnzr9kmU4jmD9FqkLXAqcd_W-U-fLyUh92F7Tnu9RBY6VI5GJSJwxVFQGkQ2hIpkQ5OmSxPIoj7T1_YjoqdOoJ8LsglQ7gULVwKhEvRwKXQEbxazzlriUguHL3XQ6PolFJVbHARwfP1ZVQnFCMyc79Y4RhqvKIpehvBgxaJ6-3SLM-IwDGC1z00N4v_-14eXXwvz2Dn8GQyLsaj6dFjuJGQiDTp0HuwXS9X_glcs9_q02r5tBE2Bp8uG7K_AcT9Y1M |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9NQEB6VFFVc2BdDASPBCZ6a2G89IARpIqK2UYRA6s213yJVgqTEDstf49cx4yURKvTWA2f7PT8n32yemW8AnkvN87woBozI6xgXwaLMiYLJ1KlB4UNwvmbXP1TTqT4-NrMt-NX1wlBZZacTa0XtFpa-ke9Rj6VA66_0XmjLImb74zdnXxlNkKJMazdOo4HIgf_5HcO38vVkH__rF0kyHn0cvmfthAFmUyUqprxxA-XQZgsfcoztre9r5xCztm-NxWAlV0F6znPpdZE7zfEUvgia-FzTJKS47xXYVuhkiB5svxtNZx_WOQyUHVHnWiWqlESKtmUn4YIa93jKGdpLhtGgMsz8aRbP-brn8rS1-Rvf-J9_uJtwvXW647eNlNyCLT-_DTtHbVnBHfgy6Ua1xIsQj35U1JK2PCWeclx25KscfejSl_FiHqPDHA9XDV86qxsAqnhTQ0Trh2hPyI7g0tnfdrkLny7lZe9Bb47PegBx4VLR7xeJwx15QDnhxhJdkQlO5VInEQw6GGS2JWmnWSGfMwrWEDpZA50MoZPV0MlMBC_Xa84aipIL797tYJK16qrMNhiJ4Nn6Mioayh7lc79Y4T00ksVQXjeC-w0q149LpZZE7RjBqw6mm83_fZaHF5_lKewgUrPDyfTgEVxLSFrqOuld6FXLlX8MV-236rRcPmklL4aTy8bsb-F4bXM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+Extraperitoneal+Metastases+on+the+Curative-Intent+Management+of+Colorectal+Peritoneal+Metastases&rft.jtitle=Annals+of+surgical+oncology&rft.au=Schell%2C+Fr%C3%A9d%C3%A9ric&rft.au=Kefleyesus%2C+Amaniel&rft.au=Benzerdjeb%2C+Nazim&rft.au=Passot%2C+Guillaume&rft.date=2023-07-01&rft.eissn=1534-4681&rft.volume=30&rft.issue=7&rft.spage=4444&rft_id=info:doi/10.1245%2Fs10434-023-13279-9&rft_id=info%3Apmid%2F36864324&rft.externalDocID=36864324 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1068-9265&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1068-9265&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1068-9265&client=summon |